Despite pricing well below range, an upsized IPO by cystic fibrosis drug developer Proteostasis Therapeutics Inc. (NASDAQ:PTI) fell 17 percent during its first day of trading Thursday, joining a small but intrepid class of four biotech IPOs this year, all of which have seen shares fall from their initial price. (See chart, below.)